Pfizer Pays $2.3 Billion to Settle Drug Dispute

Sept. 2, 2009
Dispute was over marketing of medicines for off-label purposes

To settle a dispute with the U.S. government over the marketing of medicines for off-label purposes, Pfizer has agreed to pay a record $2.3 billion, the company said on Sept. 2.

The settlement ends criminal and civil proceedings against the pharmaceutical giant arising from its advertising of four drugs, including the since-withdrawn painkiller Bextra, for unapproved purposes.

"Pfizer Inc. today announced that it has finalized a previously reported agreement in principle with the US Department of Justice (DOJ) to settle an investigation regarding past off-label promotional practices related to Bextra, which Pfizer voluntarily withdrew from the market in 2005," the company said.

Copyright Agence France-Presse, 2009

Popular Sponsored Recommendations

Navigating Disruption: A Leader’s Guide to Strategy Under Uncertainty

Nov. 1, 2023
AI, sustainability, digital--industrials are facing disruptive forces that are redefining what it takes to win. What got your company where it is today won’t get you where you...

Your Industry 4.0 Journey

Sept. 24, 2023
When It Comes to Industry 4.0, the Journey is the Destination. Industry 4.0 must be embraced as a long-term, strategic mindset of digital transformation that dynamically alters...

Food and Beverage 2024 Trends and Outlook for North America

Oct. 29, 2023
Ready to hear what 200 of your peers said are the top challenges and opportunities in 2024? Don’t fall behind. Uncover actionable insights to better prepare for 2024 in this whitepaper...

Process Mining For Dummies

Nov. 19, 2023
Here it is. Everything you need to know about process mining in a single book, written in the easy-to-understand, hard-to-forget style that ‘For Dummies’ manages so effortlessly...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!